Exosome Stability Studies

Q: What stability parameters do you monitor, and why do they matter for microbial EVs?

We monitor particle size (NTA/DLS), morphology (TEM), surface charge (Zeta potential), membrane integrity, total protein/particle concentration, and functional bioactivity. Microbial vesicles possess distinct membrane compositions—LPS, LTA, and fungal cell-wall components—that respond differently to freezing, thawing, and buffer osmolarity than mammalian EVs. Our parameter panels are therefore calibrated specifically for mEV structural and functional integrity.

Q: Can you develop a lyophilized formulation that supports room-temperature storage?

Yes. Through systematic lyoprotectant screening and cycle optimization, we routinely achieve 6–24 months of room-temperature stability, depending on strain background and payload. Deliverables include the finalized formulation composition, reconstitution protocol, and complete stability report.

Q: How many freeze-thaw cycles can microbial EVs tolerate?

It is strain-dependent. E. coli OMVs typically tolerate fewer than three cycles before measurable membrane compromise, while selected Gram-positive probiotic EVs may withstand five to eight cycles. Our reports provide the critical threshold for your specific product and recommend handling SOPs to minimize degradation.

Q: Do you accept purified EVs from external labs, or do you require in-house isolation?

We accept client-provided purified EVs and also support full-process projects starting from fermentation supernatant. For external samples, we require documentation of isolation method, buffer composition, and storage history to ensure baseline data integrity.

Q: What is the difference between physical stability and functional stability?

Physical stability refers to the retention of particle size, concentration, and morphology. Functional stability refers to the restoration of cell uptake, payload release, and bioactivity after storage or reconstitution. We validate both; a formulation is qualified only if it passes both physical and functional gates.

Q: Can you simulate real-world shipping and distribution conditions?

Yes. Our transport simulation module replicates dry-ice sublimation, transient temperature excursions, and mechanical agitation encountered during global logistics. We collect stability metrics before, during, and after simulated transit to validate that your product remains within specification.

Q: Do you provide documentation for regulatory filings?

Yes. We provide CoA, SOP summaries, batch-to-batch consistency datasets, and optional GxP-aligned CQA documentation suitable for IND submissions, cosmetic raw-material registration, and food-grade safety filings.

Q: How do I choose between liquid and lyophilized formulation?

The choice depends on your application timeline and supply-chain infrastructure. Liquid formulations are suitable for short-term use (weeks at 4°C). Lyophilized formulations are preferred for long-term storage, room-temperature distribution, and clinical or commercial scale-up where cold-chain continuity cannot be guaranteed.

Inquiry

OverviewServicesSamplesAdvantagesApplicationsCase StudyFAQs

Overview

At Creative BioMart Microbe, we provide end-to-end stability profiling and formulation development purpose-built for microbial extracellular vesicles (mEVs), including bacterial outer membrane vesicles (OMVs), probiotic-derived exosomes, fungal EVs, and phage-derived vesicles. Unlike mammalian exosome stability platforms that apply human-cell buffer systems by default, we have optimized every storage condition, lyoprotectant formulation, and stress-testing protocol for the unique lipidome, surface charge, and immunogenic architecture of microbial vesicles. Our platform integrates multi-temperature real-time monitoring, lyophilization formulation development, thermal and freeze-thaw stress profiling, buffer optimization, transport simulation, and post-storage functional recovery validation into a single, milestone-driven workflow.

Because shelf-life conclusions are only as reliable as the purity of the starting material and the sensitivity of the post-storage readout, we run every stability study in continuity with upstream Exosome Isolation & Purification and downstream Exosome Characterization & Quality Analytics. This integration is managed under our Exosome Formulation Development & Stability Solutions framework, ensuring that your formulation data are traceable to manufacturing batch records and compatible with CMC or regulatory filing requirements. Contact us to scope a custom stability program.

Scientific schematic of the integrated exosome stability platform showing sample intake, multi-temperature stability testing, lyophilization formulation with protectant screening, transport simulation, and post-storage functional recovery validation in a closed-loop QC cycle.
Figure 1. Schematic overview of the integrated exosome stability profiling and formulation development platform, spanning sample intake, multi-variable stability testing, lyophilization formulation optimization, transport simulation, and post-storage functional recovery validation with pre- and post-storage characterization closed-loop QC.

Services

Service Workflow

Horizontal seven-stage commercial workflow diagram for exosome stability studies, from project inquiry and sample receipt through baseline characterization, stability profiling, lyophilization development, transport simulation, functional validation, and final data delivery.

Inquiry

Service Details

Scientific illustration of multi-temperature stability monitoring for microbial extracellular vesicles across -80°C, -20°C, 4°C, 25°C, and 37°C with NTA, DLS, TEM, and ZetaView analysis platforms.

Storage Condition Optimization & Real-Time Stability Monitoring

We design multi-temperature and multi-timepoint stability matrices spanning −80°C, −20°C, 4°C, 25°C, and 37°C. Particle size, concentration, morphology, and surface charge are monitored at defined intervals by NTA, DLS, TEM, and ZetaView. Data are fitted to degradation kinetic models to generate shelf-life prediction curves and recommended storage limits for liquid and frozen formulations.

Scientific illustration of lyophilization formulation development for microbial exosomes showing vacuum freeze-drying cycle optimization and lyoprotectant screening with trehalose, sucrose, and mannitol candidates.

Lyophilization (Freeze-Drying) Formulation Development

We develop vacuum lyophilization protocols and screen lyoprotectant candidates including disaccharides (trehalose, sucrose), polyols (mannitol, sorbitol), and polymeric stabilizers (dextran, PEG, PVP). Post-lyophilization recovery is validated by NTA particle count, TEM morphology, and functional assays. Optimized formulations support long-term room-temperature storage with documented particle integrity and bioactivity retention.

Scientific illustration of freeze-thaw and thermal stress profiling for microbial extracellular vesicles showing repeated cycle testing and membrane integrity tracking by dye retention and Zeta-potential analysis.

Thermal Stress & Freeze-Thaw Cycle Profiling

We subject mEV samples to repeated freeze-thaw cycles (1–10 cycles) and controlled thermal stress to identify membrane compromise thresholds. Membrane integrity is tracked by membrane-dye retention, Zeta-potential drift, and particle concentration decay. Reports specify the critical freeze-thaw limit for each strain background and recommend handling SOPs to minimize degradation during manufacturing and clinical use.

Scientific illustration of buffer composition and protectant screening for microbial exosomes comparing PBS, Tris, citrate, and custom buffers across pH, ionic strength, and osmolarity ranges.

Buffer Composition & Protectant Screening

We systematically compare PBS, Tris, citrate, and custom buffers across pH, ionic strength, and osmolarity ranges to identify formulations that maximize vesicle integrity. Protectant efficacy is ranked by particle retention, aggregation index, and functional recovery. The output is a finalized formulation report with recommended storage buffer and handling conditions.

Scientific illustration of transport stability simulation and cold-chain validation for microbial exosomes showing dry-ice sublimation, temperature excursion, and mechanical agitation stress testing.

Transport Stability Simulation & Cold-Chain Validation

We simulate real-world logistics stress including dry-ice sublimation, transient temperature excursions, and mechanical agitation. Stability metrics are collected before, during, and after simulated transit to validate that mEV products retain physical and functional specifications under actual global distribution conditions.

Scientific illustration of post-storage functional recovery validation for microbial exosomes showing cell uptake efficiency, payload release kinetics, and bioactivity restoration assays.

Post-Storage Functional Recovery Validation

We distinguish physical stability from functional stability. Following storage or lyophilization, samples are reconstituted and tested for cell uptake efficiency, payload release kinetics, and bioactivity restoration (immunomodulation, enzymatic activity, or barrier repair). Only formulations that pass both physical and functional gates are qualified for downstream use.

Scientific illustration of strain-specific stability database and comparative profiling for microbial extracellular vesicles across engineered bacterial strains, GRAS probiotics, and fungal backgrounds.

Strain-Specific Stability Database & Comparative Profiling

We maintain a growing stability database across engineered bacterial strains, GRAS probiotics, and fungal backgrounds. Clients can access comparative profiling panels to select high-stability production strains prior to scale-up, or benchmark their own isolates against established baselines for batch-to-batch consistency trending.

Service Specifications & QC Standards

Stability Profiling Capability

Multi-variable matrices: temperature, time, buffer composition, freeze-thaw cycle, isolation method (TFF, SEC, ultrafiltration, density gradient), and protectant type.
Analytical platforms: NTA, DLS, TEM, ZetaView, nano-flow cytometry, BCA, ELISA, qPCR, and functional cell-based assays.
Strain coverage: E. coli OMVs, probiotic EVs, yeast/fungal EVs, and phage-derived vesicles.
Compliance: MISEV2023 stability monitoring guidelines; GxP-aligned formats available upon request.

Typical Data Range

Post-lyophilization size shift: < 15% relative to fresh sample.
Post-lyophilization particle retention: 60–90% (protectant-dependent).
Post-reconstitution functional recovery: ≥ 70% for cell uptake and immunomodulation.
Liquid formulation shelf life at 4°C: 7–30 days (unoptimized); lyophilized formulation shelf life at 25°C: ≥ 6–24 months (optimized).
Critical freeze-thaw limit: < 3 cycles for OMVs; 5–8 cycles for select probiotic EVs.
Batch-to-batch stability CV: < 15% (size/concentration); < 20% (functional activity).

Turnaround Time

Project Type	Timeline
Storage condition screening (multi-temperature, 4–8 timepoints)	2–6 weeks
Lyophilization formulation development (3–5 protectant candidates)	3–5 weeks
Freeze-thaw and thermal stress profiling	2–3 weeks
Buffer composition optimization	2–3 weeks
Transport stability simulation	2–3 weeks
Post-storage functional recovery validation	3–4 weeks
Strain-specific stability database entry (comparative panel)	4–6 weeks
Integrated stability package (storage + lyophilization + function)	6–10 weeks

Timeline may vary based on strain complexity, sample availability, and assay customization.

Deliverables

Experimental protocols and SOP summaries.
Raw data files (NTA trajectories, TEM image sets, flow-cytometry FCS files, functional assay raw reads).
Processed stability trend reports with statistical analysis, shelf-life prediction curves, and publication-ready charts.
Lyophilization formulation development report (optimal protectant blend, reconstitution protocol).
Certificate of Analysis (CoA) per batch.
Methodology summary and instrument calibration records.
Optional CQA documentation package for IND-enabling and regulatory submissions.

Quality Control

Batch-level instrument calibration with certified microsphere standards and Zeta-potential reference materials.
Inter-batch consistency assessment (size/concentration CV < 15%; functional activity CV < 20%).
MISEV2023 compliance checklist for all stability and functional assays.
Contaminant screening for residual lyoprotectant, unencapsulated free payload, and organic solvent.
Endotoxin monitoring for all in vivo–grade samples (< 0.5 EU/mL).
Optional GxP-aligned assay validation and CQA trending analysis for lot-release documentation.

Sample Requirements

Required Information	Optional Information	Not Accepted
Sample type (purified mEVs, engineered formulations, lyophilized exosomes, fermentation supernatants, conditioned media, live engineered strains) Estimated particle concentration or total protein yield Strain background and culture conditions Sample volume (≥ 500 μL recommended for in vitro; ≥ 1 mL for multi-timepoint profiling; ≥ 10 mL for large-scale lyophilization development) Endotoxin level (for in vivo studies) Target stability endpoint or shelf-life requirement	Prior isolation method (TFF, SEC, ultrafiltration, density gradient, or other) Target application (research, CMC, regulatory filing, cosmetic-grade, food-grade) Target payload type and concentration (if drug-loaded) Target storage condition (liquid nitrogen, −80°C, 4°C, room temperature) Special stability requests (fluorescent labeling, targeting ligand, clinical-supply validation) Regulatory documentation requirements (CoA, SOP, CQA package)	Samples subjected to more than three freeze-thaw cycles Samples with unidentified strain origin or undocumented culture conditions Severely degraded, contaminated, or detergent-heavy preparations Samples preserved with fixatives, antimicrobial agents, or non-sterile buffers Samples shipped at inadequate temperature or with compromised cold-chain documentation

Recommended Sample Quantity by Application:

Application	Recommended Amount
Storage condition screening (multi-temperature, multi-timepoint)	≥ 500 μg total protein or ≥ 5 × 10⁹ particles
Lyophilization formulation development	≥ 1 mg total protein or ≥ 1 × 10¹⁰ particles
Freeze-thaw and thermal stress profiling	≥ 300 μg total protein
Buffer and protectant screening	≥ 500 μg total protein
Transport stability simulation	≥ 500 μg total protein
Post-storage functional recovery validation	≥ 500 μg total protein (including functional assay requirements)
Strain-specific stability database (comparative panel)	≥ 300 μg total protein per strain; 3–5 strains recommended
Full integrated stability package (storage + lyophilization + function)	≥ 2 mg total protein

Storage & Shipping: Ship frozen at −80°C on dry ice. Store at −80°C upon receipt. Avoid repeated thawing. Recommended buffer: sterile PBS, pH 7.4, endotoxin-free. Live engineered strains should be shipped on glycerol stocks or agar stabs with cold-chain documentation. Lyophilized samples should be shipped in sealed, moisture-barrier containers with desiccant.

Inquiry

Our Advantages

Microbial EV-Specific Stability Expertise: Deep expertise in bacterial OMVs, probiotic EVs, and fungal vesicles. Every storage buffer, lyoprotectant, and stress-testing protocol is optimized for microbial membrane composition, not adapted from mammalian templates.
Physical-to-Functional Stability Closed Loop: We do not release stability data after particle-count recovery alone. Every qualified formulation is validated for post-storage cell uptake, payload release, and bioactivity restoration, ensuring that physical integrity translates to functional efficacy.
Lyophilization-to-Formulation Integration: From protectant screening and freeze-drying cycle optimization to reconstitution SOPs, we deliver complete formulation packages that enable room-temperature storage and reduce cold-chain dependency and logistics cost.
Strain-Specific Stability Database: Our comparative profiling database spans engineered bacterial, probiotic, and fungal strains, allowing clients to select high-stability production strains upstream and benchmark batch-to-batch consistency with quantitative baselines.
Transport-Validated for Global Logistics: We simulate real-world shipping stress—dry-ice sublimation, transient warming, and mechanical agitation—to generate stability evidence under actual distribution conditions, supporting clinical and commercial supply chains across North America and Europe.
Regulatory-Ready & Scale-Up Compatible: Documentation supports CMC packages, IND-enabling studies, and cosmetic or food-grade raw-material registrations. Optional GxP-aligned CQA trending and lot-release formats are available for manufacturing scale-up.

Applications

Biopharmaceutical shelf-life and CMC support application icon showing stability data reports and lyophilized formulation documentation for IND submissions.

Biopharmaceutical Shelf-Life & CMC Support

Stability data and lyophilized formulation reports for IND submissions, expiry dating, and lot-release specification setting.

Cosmetic and dermaceutical exosome formulation application icon showing room-temperature-stable cosmetic-grade exosome ingredients with percutaneous activity validation.

Cosmetic & Dermaceutical Formulation

Room-temperature-stable cosmetic-grade exosome ingredients with validated percutaneous activity retention and Product Information File (PIF) documentation support.

Probiotic and functional food exosome preservation application icon showing probiotic EV stability under GI conditions and food-processing temperatures.

Probiotic & Functional Food Preservation

Probiotic EV stability under GI conditions and food-processing temperatures, supporting functional and medical food development.

Global distribution and clinical supply chain application icon showing cross-border transport validation and clinical-site storage qualification.

Global Distribution & Clinical Supply Chain

Cross-border transport validation and clinical-site storage qualification, mitigating cold-chain risk from manufacturing to administration.

Case Study

Case Study 1: PS-Free Outer Membrane Vesicles Exhibit Enhanced Tolerability and Preserved Tumor-Targeting Stability for Modular Immunotherapy

This study engineered endotoxin-free bacterial outer membrane vesicles (OMVs) by deleting seven LPS synthesis genes in *E. coli* ClearColi BL21(DE3). Comparative characterization revealed that LPS-free OMVs maintained spherical morphology with a modest size increase to 51.31 nm versus 36.25 nm for wild-type, attributable to reduced steric stabilization. Despite eliminating detectable endotoxin activity, LPS-free OMVs retained tumor-targeting capacity equivalent to wild-type controls upon intravenous administration in MC38 tumor-bearing mice. The maximal tolerated dose improved over 25-fold, enabling high-dose regimens that achieved superior tumor suppression with three complete responders at 20 mg/kg versus one at 0.75 mg/kg for wild-type. Neo-2/15 cytokine functionalization further enhanced splenocyte proliferation 5.26-fold and CD8+ T cell expansion 32.5-fold, demonstrating that LPS removal preserves OMV structural stability while expanding the therapeutic window for engineered immunotherapy.

Characterization of LPS-free outer membrane vesicles showing schematic LPS structure variants, DLS size distribution and zeta potential, endotoxin quantification, TLR4/TLR2 activation assays, proteomic Venn diagram, tumor accumulation fluorescence imaging, and survival curves comparing wild-type versus functionalized LPS-free OMV efficacy.
Figure 2. Evaluation of LPS-attenuated and LPS-free OMV variants for anticancer immunotherapy. (Chen, et al. 2025)

Case Study 2: Gradient Filtration Doubles OMV Yield While Preserving Macrophage Uptake and Anti-Inflammatory Bioactivity

The researchers developed a gradient filtration method combining 300 nm and 100 kDa membranes to isolate outer membrane vesicles (OMVs) from probiotic Escherichia coli Nissle 1917 (EcN), achieving approximately twice the yield of traditional ultracentrifugation (2.60 × 10¹¹ versus 1.40 × 10¹¹ particles/mL by NTA; 1.23 versus 0.55 μg/μL by BCA). TEM and NTA confirmed that gradient filtration-isolated OMVs retained canonical spherical morphology with size distributions of 20–250 nm, matching ultracentrifugation controls. DiO fluorescence imaging demonstrated successful internalization by RAW264.7 macrophages, indicating preserved membrane integrity and biological activity. Cytokine profiling revealed that the purified OMVs induced both pro-inflammatory (TNF-α, IL-6, IL-1β) and anti-inflammatory (IL-10) responses, with IL-10 secretion predominating across all concentrations—consistent with literature reports for ultracentrifugation-isolated EcN OMVs. These findings establish gradient filtration as a scalable, cost-effective isolation approach that maintains OMV structural stability and immunomodulatory function.

Comparative characterization of EcN-derived OMVs isolated via gradient filtration versus ultracentrifugation.
Figure 3. Comparison of the yields of the EcN-derived OMVs obtained using ultracentrifugation and the gradient filtration method through bicinchoninic acid (BCA) protein and NTA quantification. (Li, et al. 2024)

FAQs

Q: What stability parameters do you monitor, and why do they matter for microbial EVs?

A: We monitor particle size (NTA/DLS), morphology (TEM), surface charge (Zeta potential), membrane integrity, total protein/particle concentration, and functional bioactivity. Microbial vesicles possess distinct membrane compositions—LPS, LTA, and fungal cell-wall components—that respond differently to freezing, thawing, and buffer osmolarity than mammalian EVs. Our parameter panels are therefore calibrated specifically for mEV structural and functional integrity.

Q: Can you develop a lyophilized formulation that supports room-temperature storage?

A: Yes. Through systematic lyoprotectant screening and cycle optimization, we routinely achieve 6–24 months of room-temperature stability, depending on strain background and payload. Deliverables include the finalized formulation composition, reconstitution protocol, and complete stability report.

Q: How many freeze-thaw cycles can microbial EVs tolerate?

A: It is strain-dependent. E. coli OMVs typically tolerate fewer than three cycles before measurable membrane compromise, while selected Gram-positive probiotic EVs may withstand five to eight cycles. Our reports provide the critical threshold for your specific product and recommend handling SOPs to minimize degradation.

Q: Do you accept purified EVs from external labs, or do you require in-house isolation?

A: We accept client-provided purified EVs and also support full-process projects starting from fermentation supernatant. For external samples, we require documentation of isolation method, buffer composition, and storage history to ensure baseline data integrity.

Q: What is the difference between physical stability and functional stability?

A: Physical stability refers to the retention of particle size, concentration, and morphology. Functional stability refers to the restoration of cell uptake, payload release, and bioactivity after storage or reconstitution. We validate both; a formulation is qualified only if it passes both physical and functional gates.

Q: Can you simulate real-world shipping and distribution conditions?

A: Yes. Our transport simulation module replicates dry-ice sublimation, transient temperature excursions, and mechanical agitation encountered during global logistics. We collect stability metrics before, during, and after simulated transit to validate that your product remains within specification.

Q: Do you provide documentation for regulatory filings?

A: Yes. We provide CoA, SOP summaries, batch-to-batch consistency datasets, and optional GxP-aligned CQA documentation suitable for IND submissions, cosmetic raw-material registration, and food-grade safety filings.

Q: How do I choose between liquid and lyophilized formulation?

A: The choice depends on your application timeline and supply-chain infrastructure. Liquid formulations are suitable for short-term use (weeks at 4°C). Lyophilized formulations are preferred for long-term storage, room-temperature distribution, and clinical or commercial scale-up where cold-chain continuity cannot be guaranteed.

References:

Chen, M. Y., et al. (2025). Endotoxin-free outer membrane vesicles for safe and modular anticancer immunotherapy. ACS Synthetic Biology, 14(1), 148-160.
Li, N., et al. (2024). Efficient isolation of outer membrane vesicles (OMVs) secreted by gram-negative bacteria via a novel gradient filtration method. Membranes, 14(6), 135.

Services

Inquiry